Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty

Trial Profile

Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Fracture; Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2013 New trial record
    • 01 Apr 2013 Preliminary results published in the Journal of Arthroplasty.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top